
APYX Stock Forecast & Price Target
APYX Analyst Ratings
Bulls say
Apyx Medical Corp has shown significant revenue growth in its Surgical Aesthetics segment, with expectations of reaching $43.0 million to $45.0 million, marking a 14.0% year-over-year increase at the midpoint. The overall full-year revenue guidance has been raised to between $50.5 million and $52.5 million, driven primarily by improved execution and demand trends in the Surgical Aesthetics segment. Additionally, the company is anticipating enhanced revenue contributions from the AYON launch, as sales for the quarter rose to $12.9 million, reflecting a 12% increase compared to the previous year, underscoring the positive market reception and growth potential in this sector.
Bears say
Apyx Medical Corp has experienced a decline in projected OEM sales, now forecasted at approximately $7.5 million, down from prior expectations of $8.0 million, which highlights reduced sales volumes to existing customers. Additionally, the company has faced significant operational challenges, including the lingering effects of an FDA warning letter issued in March 2022 and market pressures related to the increased use of GLP-1 medications, impacting demand in the aesthetics sector. Furthermore, Apyx Medical’s cash and cash equivalents decreased from $29.3 million at the end of Q2 2025 to $25.1 million at the end of Q3 2025, indicating potential liquidity concerns amid a volatile revenue environment heavily reliant on its Surgical Aesthetics segment.
This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
APYX Analyst Forecast & Price Prediction
Start investing in APYX
Order type
Buy in
Order amount
Est. shares
0 shares